Flashpoint Therapeutics
California-based Flashpoint Therapeutics innovates curative cancer immunotherapies.
Founded
2022California-based Flashpoint Therapeutics innovates curative cancer immunotherapies.
Flashpoint Therapeutics, founded in Redwood City, California, is dedicated to revolutionizing cancer treatment through innovative immunotherapies. Their core mission is to transform therapeutic components from ineffective to curative using advanced nanotechnology. Flashpoint focuses on developing nanotherapeutic candidates capable of co-delivering precise RNA, DNA, and peptide payloads to targeted cells at optimal times, addressing significant limitations in current cancer therapies.
Notable individuals affiliated with Flashpoint Therapeutics include leading scientists and biotech experts who drive the company's groundbreaking research. The startup has garnered attention from prominent investors in the biotech sector. Flashpoint's key achievements include the development of proprietary nanotechnology that enhances the efficacy and precision of cancer treatments, positioning the company as a pioneer in the field of curative therapeutics. Their innovative approach has the potential to significantly impact cancer treatment outcomes, offering new hope to patients worldwide.
Companies similar to Flashpoint Therapeutics include Cello Therapeutics, Nano RED, SynerGene Therapeutics and NextPoint Therapeutics.
Flashpoint Therapeutics was founded in 2022.
Flashpoint Therapeutics' headquarters is located in Redwood City, CA, US.
Flashpoint Therapeutics' most recent funding round was for $10M (USD) in October 2023.
As of Oct 25, 2023, Flashpoint Therapeutics has disclosed funding of $10M (USD). Undisclosed round amounts are excluded.
Flashpoint Therapeutics has 5 employees as of Feb 4, 2024.
NextPoint Therapeutics
nextpointtx.com
